2023 IRSF Rett Syndrome Scientific Meeting

Join us this June in Nashville for the
2023 IRSF Rett Syndrome Scientific Meeting


The IRSF Rett Syndrome Scientific Meeting returns to Nashville in 2023, bringing together scientists and researchers studying Rett syndrome and related areas from around the world. During this 2½ day meeting, attendees representing academia, industry, and governmental agencies will share their latest research advances and discuss ways to leverage learning in the lab to be rapidly deployed in the clinic.

The Rett Syndrome Scientific Meeting is the only global, comprehensive research meeting focused exclusively on Rett syndrome.

Meeting Format

This year’s annual meeting will consist of both poster and oral presentation sessions and breakout discussions focused on basic, translational, and clinical work on Rett syndrome. Between sessions, attendees will have ample time to connect, break down barriers, and forge new partnerships to advance toward treatments and a cure for Rett syndrome.

– Mon, June 5th – Full day & evening reception
– Tue, June 6th – Full day & poster session; COE Dinner (by invite)
– Wed, June 7th – Half day ends at 12pm



IRSF Rett Syndrome Scientific Meeting 2022

Keynote Speakers

Michelle Campbell, PhD

FDA (CDER) - Office of Neuroscience

As the Associate Director for Stakeholder Engagement & Clinical Outcomes, Dr. Campbell directs patient-focused drug development and the use of patient experience data in the regulatory setting.

Nathaniel Heintz, PhD

The Rockefeller University

Dr. Heintz has conducted ground-breaking research on the complexity of mammalian brain function and is known for his extensive characterization of the cells that make up the CNS.

Katherine High, MD

The Rockefeller University

Dr. High is a leader in the gene therapy field and co-founder of Spark Therapeutics, where she spearheaded the development of the first FDA approved AAV gene therapy (Luxturna).

Rudolf Jaenisch, MD

Whitehead Institute

A pioneer in the field of epigenetics and transgenics, Dr. Jaenisch developed one of the first mouse models of RTT and has conducted pivotal studies on the biology of Rett syndrome.

Jeannie Lee, MD, PhD

Massachusetts General Hospital

Dr. Lee has paved the way for X-chromosome reactivation as a potential therapeutic strategy for Rett syndrome by conducted fundamental research on the role of RNA in epigenetic silencing.

Huda Zoghbi, MD

Baylor College of Medicine

Landmark work from Dr. Zoghbi's lab identified mutations in MeCP2 as the underlying cause of Rett syndrome, a discovery that catapults the field forward to this day.


The meeting will take place at the Nashville Marriott at Vanderbilt University. For room block information, see hotel accommodation information below.

Nashville Marriott at Vanderbilt University
2555 West End Avenue
Nashville, TN 37203, US

The hotel is located 10 miles from Nashville International Airport (BNA). It is adjacent to Vanderbilt’s campus and a short distance to downtown Nashville.



Attendee Type Early Bird Price
(extended to March 24)
Regular Price
(starts March 25)
Clinician or Researcher (Non-Industry) $375 $450
Post-Doc or Student (email proof of training status) $125 $150
Industry $850 $1,000


Abstract SubmissionS

The abstract submission window is now closed. 

All accepted abstracts will be invited to present a poster, and the best will be invited to give a platform presentation. The registration fee will be waived for invited speakers.

Additional Information

Thank you to our sponsors

Presenting Sponsor

Gold Sponsor

Silver Sponsor

Bronze Sponsor


A limited number of sponsorship opportunities are still available. View the full sponsorship benefit packet below. For questions or to secure a sponsorship, please contact Melissa Kennedy at [email protected].

Download Sponsorship Packet

IRSF invites participation in the IRSF Rett Syndrome Scientific Meeting from all eligible individuals irrespective of gender, race/ethnicity, disability status, religion, or nationality. By registering for this event, all participants agree to abide by all IRSF policies as well as all applicable federal, state and local laws.

For a recap of the 2022 Meeting, CLICK HERE.

A FIRST FOR RETT: FDA approves Trofinetide for the treatment of Rett syndrome!
It’s Giving Tuesday - Go ALL IN for Rett!